Azathioprine in the treatment of myasthenia gravis | Zendy

Witte Arnold S. | Zendy; Cornblath David R. | Zendy; Parry Gareth J. | Zendy; Lisak Robert P. | Zendy; Schatz Norman J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Azathioprine in the treatment of myasthenia gravis

Author(s) -

Witte Arnold S.,

Cornblath David R.,

Parry Gareth J.,

Lisak Robert P.,

Schatz Norman J.

Publication year - 1984

Publication title -

annals of neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.764

H-Index - 296

eISSN - 1531-8249

pISSN - 0364-5134

DOI - 10.1002/ana.410150615

Subject(s) - azathioprine , medicine , myasthenia gravis , immunosuppression , immunosuppressive drug , surgery , gastroenterology , transplantation , disease

Twenty‐four patients with myasthenia gravis were treated with azathioprine. Eighteen of the patients tolerated the drug. Six discontinued azathioprine therapy because of toxicity. Of the 18 patients, 15 (83%) improved while receiving azathioprine; in 8 (44%) improvement was felt to result solely from azathioprine. Initial response was seen after 4 to 10 months of treatment, with a mean of 6.4 months. Patients continued to improve for up to 24 months, with the mean time of peak improvement being 14 months. Relapse occurred within one year in all 6 patients in whom azathioprine administration was discontinued. Azathioprine is a reasonable alternative to corticosteroids in selected myasthenic patients requiring immunosuppression.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research